Enanta Pharmaceuticals | ENTA - Assets


Enanta Pharmaceuticals reported $329.5M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.29B 585.39M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 197.42B 3.64B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Novavax USD 888M 67.57M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026